Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
ENvue Medical (NASDAQ: ENVB) announced on December 15, 2025 that David Johnson has been appointed Chairman of the Board. Johnson brings more than 30 years of healthcare leadership and board experience, including roles guiding Advanced Medical Balloons through acquisition and prior executive positions at ConvaTec and others.
The company said its 510(k) FDA-cleared feeding-tube placement system is in clinical use across 38 US hospitals, and management plans to increase hospital adoption in 2026 while pursuing additional 510(k) clearances to expand into neonatal and pediatric markets.
Enveric Biosciences (NASDAQ: ENVB) closed the exercise of outstanding warrants for an aggregate of 426,390 shares, raising approximately $3.1 million in gross proceeds prior to fees and expenses. The exercised warrants issued in Feb and Sep 2025 had original strike prices of $36.00 and $10.98, respectively, and were exercised at a reduced $7.05 per share.
In connection with the cash exercises and a $0.125 per-warrant payment (aggregate $106,597.50 included in gross proceeds), the company issued new unregistered series E warrants (5-year term) and series F warrants (18-month term), both exercisable immediately at $7.05. H.C. Wainwright acted as placement agent. Net proceeds are intended for product development, working capital, and general corporate purposes. The company will file a resale registration statement covering shares issuable upon exercise of the new warrants.
Enveric Biosciences (NASDAQ: ENVB) announced definitive agreements for the immediate exercise of outstanding warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, generating expected gross proceeds of approximately $3.1 million (before fees and expenses).
In connection with the exercises, the company will issue new unregistered Series E and Series F warrants (each to purchase up to 426,390 shares) with exercise price $7.05; Series E expires five years after the resale registration effective date and Series F expires 18 months after that date. The offering is expected to close on or about December 12, 2025.
Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on December 9, 2025 for a patent application covering its EVM301 Series of molecules titled “N-heterocycle substituted tryptamine derivatives and methods of using.”
The allowance will add to Enveric’s patent portfolio, covering compositions and methods of use for additional neuroplastogenic, non-hallucinogenic molecules and is described as reinforcing intellectual property around lead asset EB-003, which the company says is designed to engage 5-HT2A and 5-HT1B receptors to provide fast-acting antidepressant and anxiolytic effects while minimizing hallucinogenic effects.
Enveric Biosciences (NASDAQ: ENVB) will present and participate in a panel at the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during J.P. Morgan Week in San Francisco and will attend Biotech Showcase 2026 from January 12–14, 2026 at the Hilton San Francisco Union Square. Management plans one-on-one meetings with registered investors and potential partners to highlight the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Event details include the panel titled "Meeting the Promise of Psychedelics Panel: Expected Trends for 2026" at the Marines’ Memorial Club and registration links for both events.
Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on November 26, 2025 for a U.S. patent application covering its EVM401 Series of molecules.
The allowed application, entitled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," will be the fourth U.S. patent for the EVM401 program and is described as broadening claims to additional potential non-hallucinogenic neuroplastogenic molecules aimed at neuropsychiatric and addiction disorders. The company said the allowance, once issued as a patent, expands its intellectual property estate and strengthens its pipeline of next-generation, non-hallucinogenic neuroplastogens.
Enveric Biosciences (NASDAQ: ENVB) reported Q3 2025 results and operational progress toward an IND for lead candidate EB-003. Key clinical and CMC milestones include completion of pre-IND dose range finding studies establishing a maximum tolerated dose, positive preclinical PTSD model data (significant reduction in context-induced freezing, p < 0.05), receipt of an FDA written response to a pre-IND meeting request, and production of a 1-kilogram pharmaceutically compatible salt batch to support IND-enabling work.
Corporate actions: issued and pursued patents, hired outside counsel to defend U.S. Patent No. 12,138,276, relocated headquarters to Cambridge, MA, completed warrant exercises generating approximately $2.2 million gross, completed a reverse 1-for-12 stock split after a Nasdaq bid-price deficiency, and reported Q3 net loss of $3.4 million with $3.8 million cash as of September 30, 2025.
Enveric Biosciences (NASDAQ: ENVB) will effect a 1-for-12 reverse stock split, effective at 8:00 a.m. New York time on October 28, 2025. The company received a Nasdaq delisting determination on October 22, 2025 related to minimum bid price, and the Board approved the 1-for-12 ratio under a previously authorized 1-for-5 to 1-for-50 range.
The reverse split will convert every 12 pre-split shares into one post-split share, reduce outstanding common stock from 6,219,568 to approximately 518,297 shares, and apply proportional adjustments to equity awards and warrants. Fractional shares will be rounded up to whole shares.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of its 23rd U.S. patent from the USPTO, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.”
The patent covers a unique series of neuroplastogenic small-molecule compounds designed to target key serotonin receptors and promote neuroplasticity, expanding Enveric’s intellectual property footprint and supporting potential pipeline expansion for treatments of psychiatric and neurological disorders.
Enveric Biosciences (NASDAQ: ENVB) said it retained Fish and Richardson to defend U.S. Patent No. 12,138,276 (the ‘276 patent) after a Post‑Grant Review petition was filed by Gilgamesh Pharmaceuticals on claims that appear relevant to Bretisilocin (GM‑2505), which AbbVie agreed to acquire on August 25, 2025 in a definitive transaction valued at up to $1.2 billion. The ‘276 family includes one issued U.S. patent, additional pending U.S. and international applications, and is separate from Enveric’s EB‑003 patent families.
Enveric reported an intellectual property portfolio of 26 issued U.S. patents and 60 pending national and international applications, multiple programs advancing toward clinical development, and out‑license agreements with potential aggregate milestones of up to $205 million plus royalties.